Drug developer MapLight prices US IPO at $17 per share
26/10/2025 21:37
Oct 26 (Reuters) - MapLight Therapeutics MPLT.O, a clinical-stage biotech backed by Novo Holdings, said on Sunday it has priced its U.S. initial public offering at $17 per share. (Reporting by Angela Christy in Bengaluru; Editing by Nia Williams) ((AngelaChristy.M@thomsonreuters.com;))
Recent news on MapLight Therapeutics
See all newsUS and German scientists win Nobel medicine prize for work on light and brain (updated)
U.S. RESEARCH ROUNDUP- BioLife Solutions, Gossamer Bio, Intuit
MapLight's schizophrenia drug fails once-daily test, shares plunge
U.S. RESEARCH ROUNDUP-Deckers Brands, Rollins, United Rentals
U.S. STOCKS ON THE MOVE-Abbvie, AMC, Getty